Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients
We demonstrated that in diabetes mellitus patients concurrently experiencing acute kidney disease, DPP4i usage could decrease the risk of mortality, MAKEs, MACEs, and re-dialysis. These findings emphasize the pivotal role of tailored treatment strategies involving DPP4i for acute kidney disease patients.
Authors
- Chung‐Yi Cheng (ORCID: https://orcid.org/0000-0003-1816-7215)
- Heng‐Chih Pan (ORCID: https://orcid.org/0000-0001-5782-7138)
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Hung‐Wei Liao (ORCID: https://orcid.org/0000-0003-3090-1937)
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
- Hsing‐Yu Chen (ORCID: https://orcid.org/0000-0001-7897-9851)
- Tao‐Min Huang
Institutions
- National Taiwan University (TW)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- Primary HealthCare (MT)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Wan Fang Hospital (TW)
- Taipei Medical University (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1093/ckj/sfae385
- Citations
- 2
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.68
Funders
- National Science Council
- Taipei Medical University
- National Taiwan University Hospital
- National Taiwan University
- Wan Fang Hospital